A predictive model reveals potential microbe-drug associations, indicating new avenues for antimicrobial discovery.
Introduction Uncharted microbe-drug relationships constitute an under-exploited reservoir of therapeutic leads. In this manuscript, we introduced a hybrid framework named BRMDA by coupling a bilinear attention network with a random-forest classifier to systematically expose latent microbe-drug associations. Methods Firstly, BRMDA integrated multiple drug-centric, microbe-centric, and disease-centric similarity profiles, along with experimentally validated microbe–drug associations, to construct a unified heterogeneous graph. And then, the bilinear attention network and random-forest classifier were employed to compute the predicted scores for potential microbe-drug associations based on the newly constructed unified heterogeneous graph. Next, benchmarking experiments were conducted under a rigorous five-fold cross-validation protocol using the MDAD dataset to validate the prediction performance of BRMDA. Additionally, case studies were further performed, focusing on front-line antibiotics including amoxicillin and ciprofloxacin as well as clinically relevant pathogens including Bacillus cereus and Mycobacterium tuberculosis , to evaluate the translational validity of the proposed model. Conclusion Intensive experimental results demonstrated that BRMDA outperformed seven state-of-the-art competitors in terms of both AUC and AUPR, and 9 out of the top 10 associations predicted by the model were corroborated by independent literature evidence. These findings underscored the accuracy and translational potential of BRMDA, offering a data-driven compass for antimicrobial discovery and microbe-oriented therapeutic design.
No takes yet. Share an insight, caveat, or question.
Yu et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: